CD147

Creative Biolabs provides customers with a wide range of CD147 CAR-related products to support CART projects. Below are some of our CD147 CAR products for customers' reference. You can also search for products you are interested in by searching for the corresponding keywords.

Background

CD147, known as a tumor-associated antigen, is a highly glycosylated transmembrane immunoglobulin that is broadly and specifically expressed in a variety of tumor types, including hepatocellular carcinoma, non-small cell lung cancer, and breast cancer. CD147 is involved in tumorigenesis processes, including tumor cell invasion, metastasis, and angiogenesis. Focusing on these characteristics, CD147 has been proposed as a potential therapeutic target for many cancers.

Associated Diseases

• Breast cancer
• Glioma
• Hepatocellular carcinoma
• Non-small cell lung cancer

Anti-CD147 CAR-T Services

CD147 CAR Design & Construction

For different targets and project requirements, it is crucial to select the appropriate CAR structure. Leveraged by years of experience in the field of CART, Creative Biolabs offers a variety of effective CAR structural designs to assist our customers in their projects, such as classical CAR designs, and special armored CAR designs.

Fig.1 Schematic diagram of the CD147 CAR construction.¹

Anti-CD147 CAR-T In Vitro Assays

Anti-CD147 CAR-T Expression Test

CAR expression testing helps us to ensure that the specific CAR-T cells express the appropriate receptors and molecules at the correct levels, which is crucial for their function and survival. We utilize many different approaches (e.g., flow cytometry, western blot, and qPCR) to test CAR expression.

Fig.2 CAR expression test of CD147-CART cells by flow cytometry using anti-protein L antibody.¹

Phenotype Analysis of Anti-CD147 CAR-T

To assess the performance of CART cells in response to specific stimuli, we have developed various robust phenotypic analysis services to assist CART development, such as activation test, exhaustion detection, and cell subsets test.

Fig.3 Activation marker test of CD147-CART cells by flow cytometry.¹

Anti-CD147 CAR-T Cytokine Release Test

Cytokine release test is a commonly used assay to assess the ability of CAR-T cells to produce and release cytokines in response to specific stimuli. Creative Biolabs is committed to providing various convenient and sensitive cytokine tests for customers to choose from, such as intracellular cytokine flow detection, and multiple cytokine arrays.

Fig.4 Cytokine detection of CD147 CAR-T co-cultured with various target cells by multiple cytokine profiling.¹

Anti-CD147 CAR-T In Vitro Cytotoxicity Assay

In vitro tumor cell killing experiments evaluate the target specificity and effectiveness of CART cells against tumor cells, providing relevant data references for in vivo efficacy studies. By utilizing various means, Creative Biolabs offers a variety of effective cytotoxicity testing services to verify the tumor-killing potential of CART cells.

Fig.5 In vitro killing test of anti-CD147 CAR-T cells against different tumor cells at indicated E:T ratio.¹

Anti-CD147 CAR-T In Vivo Assays

Efficacy Test of Anti-CD147 CAR-T

To further assess the efficacy of CART cells against targeted tumors in vivo, Creative Biolabs offers a comprehensive range of appropriate animal models and in vivo experimental designs to verify the potent anti-tumor activity of CAR-T cells via multiple approaches. Considering the safety of CART therapy in the living organism, we also provide relevant toxicity evaluation services to assist CART development.

CDX Model for CD147 CAR-T

Fig.6 In vivo anti-tumor activity of CD147-CART cells in A549 CDX models. (A) In vivo experimental design diagram of CD147-CART in CDX model. Living imaging (B) and the dynamic measurement curves of tumor volume (C) and mouse weight (D) in A549 CDX models with CD147 CART treatment.¹

PDX Model for CD147 CAR-T

Fig.7 In vivo anti-tumor activity of CD147-CART cells in PDX models. (A) In vivo experimental design diagram of CD147-CART in PDX model. The dynamic measurement curves of tumor volume (B) and mouse weight (C) in PDX models with CD147-CART treatment.¹

Reference

1. Chen, Xiao-Hong, et al. "Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy." Translational oncology 16 (2022): 101309.